334 related articles for article (PubMed ID: 30768787)
1. Anti-N and anti-Do
Unnikrishnan A; Pelletier JPR; Bari S; Zumberg M; Shahmohamadi A; Spiess BD; Michael MJ; Harris N; Harrell D; Mandernach MW
Transfusion; 2019 Jun; 59(6):1907-1910. PubMed ID: 30768787
[TBL] [Abstract][Full Text] [Related]
2. Delayed hemolytic transfusion reaction/hyperhemolysis syndrome in children with sickle cell disease.
Talano JA; Hillery CA; Gottschall JL; Baylerian DM; Scott JP
Pediatrics; 2003 Jun; 111(6 Pt 1):e661-5. PubMed ID: 12777582
[TBL] [Abstract][Full Text] [Related]
3. Hyperhemolysis syndrome in a patient without a hemoglobinopathy, unresponsive to treatment with eculizumab.
Gupta S; Fenves A; Nance ST; Sykes DB; Dzik WS
Transfusion; 2015 Mar; 55(3):623-8. PubMed ID: 25257194
[TBL] [Abstract][Full Text] [Related]
4. Successful Outcome of Hyperhemolysis in Sickle Cell Disease following Multiple Lines of Treatment: The Role of Complement Inhibition.
Vlachaki E; Gavriilaki E; Kafantari K; Adamidou D; Tsitsikas D; Chasapopoulou E; Anagnostopoulos A; Tsapas A
Hemoglobin; 2018; 42(5-6):339-341. PubMed ID: 30626228
[TBL] [Abstract][Full Text] [Related]
5. Immuno-hematological findings in Delayed Hemolytic Transfusion Reaction (DHTR).
Thonier V
Transfus Clin Biol; 2019 May; 26(2):102-108. PubMed ID: 30885514
[TBL] [Abstract][Full Text] [Related]
6. Rituximab for prevention of delayed hemolytic transfusion reaction in sickle cell disease.
Noizat-Pirenne F; Bachir D; Chadebech P; Michel M; Plonquet A; Lecron JC; Galactéros F; Bierling P
Haematologica; 2007 Dec; 92(12):e132-5. PubMed ID: 18055978
[TBL] [Abstract][Full Text] [Related]
7. Red blood cell alloimmunization and delayed hemolytic transfusion reactions in patients with sickle cell disease.
Balbuena-Merle R; Hendrickson JE
Transfus Clin Biol; 2019 May; 26(2):112-115. PubMed ID: 30857806
[TBL] [Abstract][Full Text] [Related]
8. Clinical significance of RBC alloantibodies and autoantibodies in sickle cell patients who received transfusions.
Aygun B; Padmanabhan S; Paley C; Chandrasekaran V
Transfusion; 2002 Jan; 42(1):37-43. PubMed ID: 11896310
[TBL] [Abstract][Full Text] [Related]
9. Management of delayed hemolytic transfusion reaction in sickle cell disease: Prevention, diagnosis, treatment.
Pirenne F; Bartolucci P; Habibi A
Transfus Clin Biol; 2017 Sep; 24(3):227-231. PubMed ID: 28669521
[TBL] [Abstract][Full Text] [Related]
10. Life-threatening delayed hyperhemolytic transfusion reaction in a patient with sickle cell disease: effective treatment with eculizumab followed by rituximab.
Boonyasampant M; Weitz IC; Kay B; Boonchalermvichian C; Liebman HA; Shulman IA
Transfusion; 2015 Oct; 55(10):2398-403. PubMed ID: 25989361
[TBL] [Abstract][Full Text] [Related]
11. Anti-HI can cause a severe delayed hemolytic transfusion reaction with hyperhemolysis in sickle cell disease patients.
Ibanez C; Habibi A; Mekontso-Dessap A; Chadebech P; Chami B; Bierling P; Galactéros F; Rieux C; Nataf J; Bartolucci P; Peyrard T; Pirenne F
Transfusion; 2016 Jul; 56(7):1828-33. PubMed ID: 27145018
[TBL] [Abstract][Full Text] [Related]
12. Clinical presentation of delayed hemolytic transfusion reactions and hyperhemolysis in sickle cell disease.
Fasano RM; Miller MJ; Chonat S; Stowell SR
Transfus Clin Biol; 2019 May; 26(2):94-98. PubMed ID: 30837199
[TBL] [Abstract][Full Text] [Related]
13. Extended phenotyping does not preclude the occurrence of delayed haemolytic transfusion reactions in sickle cell disease.
Gerritsma J; Bongaerts V; Eckhardt C; Heijboer H; Nur E; Biemond B; van der Schoot E; Fijnvandraat K;
Br J Haematol; 2022 Feb; 196(3):769-776. PubMed ID: 34632580
[TBL] [Abstract][Full Text] [Related]
14. Alloimmunization and hyperhemolysis in sickle cell disease.
Pirenne F; Pondarré C
Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):653-659. PubMed ID: 38066873
[TBL] [Abstract][Full Text] [Related]
15. Alloimmunization in patients with sickle cell disease and underrecognition of accompanying delayed hemolytic transfusion reactions.
Coleman S; Westhoff CM; Friedman DF; Chou ST
Transfusion; 2019 Jul; 59(7):2282-2291. PubMed ID: 31021439
[TBL] [Abstract][Full Text] [Related]
16. Posttransfusion hyperhemolysis is arrested by targeting macrophage activation with novel use of Tocilizumab.
Lee LE; Beeler BW; Graham BC; Cap AP; Win N; Chen F
Transfusion; 2020 Jan; 60(1):30-35. PubMed ID: 31642065
[TBL] [Abstract][Full Text] [Related]
17. Acute Hyperhemolysis Syndrome in a Patient with Known Sickle Cell Anemia Refractory to Steroids and IVIG Treated with Tocilizumab and Erythropoietin: A Case Report and Review of Literature.
Menakuru SR; Priscu A; Dhillon V; Salih A
Hematol Rep; 2022 Jul; 14(3):235-239. PubMed ID: 35893156
[TBL] [Abstract][Full Text] [Related]
18. Delayed hemolytic transfusion reactions in sickle cell disease: simultaneous destruction of recipients' red cells.
King KE; Shirey RS; Lankiewicz MW; Young-Ramsaran J; Ness PM
Transfusion; 1997 Apr; 37(4):376-81. PubMed ID: 9111274
[TBL] [Abstract][Full Text] [Related]
19. Catastrophic Delayed Hemolytic Transfusion Reaction in a Patient With Sickle Cell Disease Without Alloantibodies: Case Report and Review of Literature.
Jasinski S; Glasser CL
J Pediatr Hematol Oncol; 2019 Nov; 41(8):624-626. PubMed ID: 30179992
[TBL] [Abstract][Full Text] [Related]
20. Complement activation during intravascular hemolysis: Implication for sickle cell disease and hemolytic transfusion reactions.
Merle NS; Boudhabhay I; Leon J; Fremeaux-Bacchi V; Roumenina LT
Transfus Clin Biol; 2019 May; 26(2):116-124. PubMed ID: 30879901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
